Intellia Therapeutics Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-02-25 09:51:59 ET
More on Intellia Therapeutics
- Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
- Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate
- Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Rare disease pharmas could benefit from FDA guidance to accelerate development
- Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug
Read the full article on Seeking Alpha
For further details see:
Intellia Therapeutics Q4 2025 Earnings Preview
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
0.03% G/L:
$12.73 Last:
1,289,650 Volume:
$13.02 Open:
NTLA Latest News
March 03, 2026 07:30:00 am
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
March 02, 2026 07:30:00 am
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
